Heart Rate Monitoring by Wearable Devices in Graves' Disease
Heart Rate Monitoring by Wearable Devices in Graves' Disease
A multi center randomized controlled study including 3 arms (wearable device group, control
 group 1, control group 2). This study is to investigate clinical feasibility of heart rate
 monitoring using wearable devices to detect disease recurrence in the patients who
 discontinue anti-thyroid drugs in remission state.
A multi center randomized controlled study including 3 arms (wearable device group, control
 group 1, control group 2).

 Study participants: Patients with Graves' disease who are planned to discontinue anti-thyroid
 drugs in remission state Wearable device group: Participants use wearable device and their
 heart rate and activity are monitored. If their resting heart rate (rHR) increase beyond the
 set range or they have hyperthyroid symptoms and signs, they should come to the hospital and
 get tests for thyroid function. If their rHR stay within set range and they have no symptoms
 and signs, they come to hospital and get tests for thyroid function 6 months after
 discontinuing anti-thyroid drugs.

 Control group 1: Participants don't use wearable devices. If they have hyperthyroid symptoms
 and signs, they should come to the hospital and get tests for thyroid function. If they have
 no symptoms and signs, they come to hospital and get tests for thyroid function 6 months
 after discontinuing anti-thyroid drugs.

 Control group 2: Participants don't use wearable devices. If they have hyperthyroid symptoms
 and signs, they should come to the hospital and get tests for thyroid function. If they have
 no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6
 months after discontinuing anti-thyroid drugs.

 A period to detecting disease recurrence, thyroid function test and Hyperthyroid Symptom
 Scale (HSS) at the time of disease recurrence, and the number of hospital visit and medical
 cost until detecting disease recurrence will be compared among 3 groups.
Inclusion Criteria:

 -  Patients with Graves' disease who are being treated with anti-thyroid drugs (ATDs) and
 planned to discontinue ATDs

 -  Those who have who have continued to administer ATDs for more than 1 year

 -  Those who showed normal findings on thyroid function tests while maintaining stable
 doses of ATDs in the last 3 months

 -  Those who can use wearable devices and smartphone apps to work with during the
 research period

 Exclusion Criteria:

 -  Those with heart disease, such as arrhythmia, that can affect heart rate

 -  Those who are taking medications that may affect their heart rate

 -  Those who researchers deemed unsuitable for participation